Will enhance company’s synthetic ceramides portfolio delivered by Sederma, drawing on Solus’ existing biotech-derived ceramide and phospholipid technologies.
The reported $700 million deal is primed to buttress the significant growth trajectories of each brand who together registered retail sales of $366 million.